Literature DB >> 24707455

IL-6 signalling in patients with acute ST-elevation myocardial infarction.

Vibeke N Ritschel1, Ingebjørg Seljeflot1, Harald Arnesen1, Sigrun Halvorsen2, Thomas Weiss3, Jan Eritsland2, Geir Ø Andersen4.   

Abstract

Cytokines of the IL-6 family have been related to infarct size and prognosis in patients with myocardial infarction. The aims of the present study were to elucidate possible associations between myocardial necrosis and left ventricular impairment and members of the IL-6 transsignalling system including soluble (s) IL-6R and (s) glycoprotein 130 (sgp130) in patients with ST-elevation myocardial infarction (STEMI) treated with primary PCI. In blood samples from 1028 STEMI patients, collected in-hosptial, we found significant correlations between peak TnT and IL-6 and CRP (p < 0.001, all) and between IL-6 and CRP and LV ejection fraction and NT-proBNP (p < 0.001, all). On the contrary, no significant associations were found between peak TnT and sgp130 or sIL-6R. Furthermore sgp130 was significantly elevated in diabetic patients and also associated with the glucometabolic state. In conclusion, circulating levels of IL-6 and CRP, but not the soluble forms of the receptor (sIL-6R) or the receptor signalling subunit (sgp130) were associated with the extent of myocardial necrosis. The biological importance of the IL-6/gp130-mediated signalling pathways in patients with acute myocardial infarction and dysglycemia should be further elucidated.

Entities:  

Keywords:  IL-6; LVEF, left ventricular ejection fraction; Myocardial necrosis; PCI, percutaneous coronary intervention; ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; sIL-6R; sIL-6R, soluble interleukin -6 receptor; sgp130; sgp130, soluble glycoprotein 130

Year:  2013        PMID: 24707455      PMCID: PMC3973821          DOI: 10.1016/j.rinim.2013.11.002

Source DB:  PubMed          Journal:  Results Immunol        ISSN: 2211-2839


  28 in total

1.  Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial.

Authors:  Sean van Diepen; Matthew T Roe; Renato D Lopes; Amanda Stebbins; Stefan James; L Kristin Newby; David J Moliterno; Franz-Josef Neumann; Justin A Ezekowitz; Kenneth W Mahaffey; Judith S Hochman; Christian W Hamm; Paul W Armstrong; Pierre Theroux; Christopher B Granger
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

2.  Plasma soluble gp130 levels are increased in older subjects with metabolic syndrome. The role of insulin resistance.

Authors:  Giovanni Zuliani; Matteo Galvani; Marcello Maggio; Stefano Volpato; Stefania Bandinelli; Anna Maria Corsi; Fulvio Lauretani; Antonio Cherubini; Jack M Guralnik; Renato Fellin; Luigi Ferrucci
Journal:  Atherosclerosis       Date:  2010-11       Impact factor: 5.162

3.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.

Authors:  T Jostock; J Müllberg; S Ozbek; R Atreya; G Blinn; N Voltz; M Fischer; M F Neurath; S Rose-John
Journal:  Eur J Biochem       Date:  2001-01

4.  Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.

Authors:  Pierre Théroux; Paul W Armstrong; Kenneth W Mahaffey; Judith S Hochman; Kevin J Malloy; Scott Rollins; Jose C Nicolau; Joel Lavoie; The Minh Luong; Jeb Burchenal; Christopher B Granger
Journal:  Eur Heart J       Date:  2005-05-04       Impact factor: 29.983

Review 5.  Interleukin-6 biology is coordinated by membrane bound and soluble receptors.

Authors:  Stefan Rose-John
Journal:  Acta Biochim Pol       Date:  2003       Impact factor: 2.149

6.  C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction.

Authors:  Stein Ørn; Cord Manhenke; Thor Ueland; Jan K Damås; Tom Eirik Mollnes; Thor Edvardsen; Pål Aukrust; Kenneth Dickstein
Journal:  Eur Heart J       Date:  2009-03-19       Impact factor: 29.983

7.  Cytokines in patients with ischaemic heart disease or myocardial infarction.

Authors:  Anna Bossowska; Beata Kiersnowska-Rogowska; Artur Bossowski; Bogdan Galar; Piotr Sowiński
Journal:  Kardiol Pol       Date:  2003-08       Impact factor: 3.108

8.  Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure.

Authors:  Hisao Hirota; Masahiro Izumi; Tomoyuki Hamaguchi; Shoko Sugiyama; Eiki Murakami; Keita Kunisada; Yasushi Fujio; Yuichi Oshima; Yoshikazu Nakaoka; Keiko Yamauchi-Takihara
Journal:  Heart Vessels       Date:  2004-09       Impact factor: 2.037

9.  CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up.

Authors:  Marianne Hartford; Olof Wiklund; Lillemor Mattsson Hultén; Elisabeth Perers; Anita Person; Johan Herlitz; Eva Hurt-Camejo; Thomas Karlsson; Kenneth Caidahl
Journal:  Int J Cardiol       Date:  2006-03-22       Impact factor: 4.164

Review 10.  Cytokines in the pathogenesis of atherosclerosis.

Authors:  James L Young; Peter Libby; Uwe Schönbeck
Journal:  Thromb Haemost       Date:  2002-10       Impact factor: 5.249

View more
  22 in total

1.  Association between interleukin-6 and the risk of cardiac events measured by coronary computed tomography angiography.

Authors:  Lei Zhao; Xilin Wang; Yuhai Yang
Journal:  Int J Cardiovasc Imaging       Date:  2017-02-24       Impact factor: 2.357

2.  Association of interleukin 8 and myocardial recovery in patients with ST-elevation myocardial infarction complicated by acute heart failure.

Authors:  Trygve Husebye; Jan Eritsland; Harald Arnesen; Reidar Bjørnerheim; Arild Mangschau; Ingebjørg Seljeflot; Geir Øystein Andersen
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

3.  Circulating Levels of IL-6 Receptor and gp130 and Long-Term Clinical Outcomes in ST-Elevation Myocardial Infarction.

Authors:  Vibeke N Ritschel; Ingebjørg Seljeflot; Harald Arnesen; Sigrun Halvorsen; Jan Eritsland; Morten W Fagerland; Geir Ø Andersen
Journal:  J Am Heart Assoc       Date:  2016-06-13       Impact factor: 5.501

4.  Early kinetics of serum Interleukine-17A and infarct size in patients with reperfused acute ST-elevated myocardial infarction.

Authors:  Thomas Bochaton; Nathan Mewton; NDieme Thiam; Fabien Lavocat; Delphine Baetz; Nathalie Dufay; Cyril Prieur; Eric Bonnefoy-Cudraz; Pierre Miossec; Michel Ovize
Journal:  PLoS One       Date:  2017-11-22       Impact factor: 3.240

5.  Prazosin protects myocardial cells against anoxia-reoxygenation injury via the extracellular signal‑regulated kinase signaling pathway.

Authors:  Lixin Wang; Yan Xue; Hao Ma; Haiyan Shi; Ling Wang; Xiaozheng Cui
Journal:  Mol Med Rep       Date:  2017-11-28       Impact factor: 2.952

6.  Evaluation of circulating levels of CCN2/connective tissue growth factor in patients with ST-elevation myocardial infarction.

Authors:  Vibeke Ritschel; Christian Shetelig; Ingebjørg Seljeflot; Shanmuganathan Limalanathan; Pavel Hoffmann; Sigrun Halvorsen; Harald Arnesen; Jan Eritsland; Geir Øystein Andersen
Journal:  Sci Rep       Date:  2017-09-20       Impact factor: 4.379

7.  The Inflammasome Signaling Pathway Is Actively Regulated and Related to Myocardial Damage in Coronary Thrombi from Patients with STEMI.

Authors:  Jostein Nordeng; Hossein Schandiz; Svein Solheim; Sissel Åkra; Pavel Hoffman; Borghild Roald; Bjørn Bendz; Harald Arnesen; Ragnhild Helseth; Ingebjørg Seljeflot
Journal:  Mediators Inflamm       Date:  2021-05-27       Impact factor: 4.711

8.  Ex vivo Ikkβ ablation rescues the immunopotency of mesenchymal stromal cells from diabetics with advanced atherosclerosis.

Authors:  Ozge Kizilay Mancini; David N Huynh; Liliane Menard; Dominique Shum-Tim; Huy Ong; Sylvie Marleau; Ines Colmegna; Marc J Servant
Journal:  Cardiovasc Res       Date:  2021-02-22       Impact factor: 10.787

9.  Interleukin-6 signaling in patients with chronic heart failure treated with cardiac resynchronization therapy.

Authors:  Katarzyna Ptaszynska-Kopczynska; Anna Szpakowicz; Marta Marcinkiewicz-Siemion; Anna Lisowska; Ewa Waszkiewicz; Marcin Witkowski; Piotr Jakim; Bogdan Galar; Wlodzimierz J Musial; Karol A Kamiński
Journal:  Arch Med Sci       Date:  2016-03-17       Impact factor: 3.318

10.  Expression of pericardial fluid T-cells and related inflammatory cytokines in patients with chronic heart failure.

Authors:  Reinard Iskandar; Shengchen Liu; Fei Xiang; Wen Chen; Liangpeng Li; Wei Qin; Fuhua Huang; Xin Chen
Journal:  Exp Ther Med       Date:  2017-03-08       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.